PRME vs TECH · rev $3.0M vs P/E 65, rev $1.22B
Prime Medicine, Inc. Common Stock (PRME) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported PRME revenue for 2024-12-31 was $3.0M. Net income was -$195.9M. PRME currently screens at market cap $570.8M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
PRME currently screens at market cap $570.8M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the PRME and TECH stock pages for the full models.
Not investment advice.